A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes

Phase 2 Not yet recruiting 200 enrolled BrightGene Bio-Medical Technology Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy of BGM0504 tablets compared with placebo in reducing body weight in overweight or obese participants without diabetes after 20 weeks of treatment.

Timeline

Start: 2026-06-30
Primary completion: 2027-02-28
Completion: 2027-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BGM0504 tablets	Unknown	—	Oral

Indications

No indication recorded.